6533b85ffe1ef96bd12c1b47

RESEARCH PRODUCT

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition.

Donatella FerraroVito Di MarcoNoemi UroneGiuseppina Maria Elena Colomba

subject

Settore MED/07 - Microbiologia E Microbiologia ClinicaT-Lymphocyteslcsh:QR1-502Bayesian analysisHepacivirusViral Nonstructural Proteinslcsh:MicrobiologyCoalescent theoryphylodynamicGenotypegenetic variabilityPhylogenyBayesian analysimedia_commonSettore MED/12 - Gastroenterologiavirus diseasesMiddle Agedviral epitopeHepatitis CHost-Pathogen InteractionInfectious Diseasesmedicine.anatomical_structureHost-Pathogen InteractionsHCVtMRCADrugAdultGenotypemedicine.drug_classmedia_common.quotation_subjectT cellmacromolecular substancesHuman leukocyte antigenBiologyAntiviral AgentsArticleYoung AdultT cell recognitionVirologyDrug Resistance ViralmedicineHumansGenetic variabilitygenotype 4AgedDAAAntiviral AgentHepaciviruVirologydigestive system diseasesviral epitopesAntiviral drugCD8RAS

description

Therapies for HCV care could change the prevalence and the geographic distribution of genotypes due to differences in Sustained Virologic Response (SVR). In this scenario, uncommon genotypes/subtypes, such as genotype 4, could spread from high-risk groups, replacing genotypes eradicated by antiviral drugs. Genotype eradication is also strongly influenced by the CD8+ T cell response. In this study, the genetic variability in HCV genotype 4 strains obtained from a cohort of 67 patients na&iuml

yearjournalcountryeditionlanguage
2020-11-28Viruses
10.3390/v12121363https://pubmed.ncbi.nlm.nih.gov/33260596